Rituximab in Patients With Relapsed or Refractory TTP-HUS
Status:
Unknown status
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The general objective of this study is to assess the efficacy and safety of Rituximab in the
management of patients with refractory or relapsed thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome (TTP-HUS). There have been several case reports and case
series describing the use of Rituximab in patients with TTP-HUS; however its use has not been
studied in a large trial. It is hypothesized that Rituximab may ameliorate the severity of
certain cases of TTP-HUS by decreasing the number of activity of B-cells which may result in
decreased production of the ADAMTS13 protease inhibitor. Patients with TTP-HUS not responding
to standard therapy or patients with relapsed disease may have particular benefit. Treatments
that decrease the frequency of relapse or shorten the time to remission of TTP-HUS will be of
benefit by decreasing the need for blood product support.
Phase:
Phase 2
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
Canadian Apheresis Group Hoffmann-La Roche McMaster University